Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages

Journal of Immunology

Volumn 175, Issue 3, 2005, Pages 1523-1531

  Jin, S L Catherine ^a   Lan, Linda ^a   Zoudilova, Maria ^a   Conti, Marco ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FORSKOLIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; ROFLUMILAST; ROLIPRAM; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOPRECIPITATION; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARALOGY; PERITONEUM MACROPHAGE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECOND MESSENGER; SHOCK; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; SURVIVAL; WESTERN BLOTTING;

EID: 22544470866     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.3.1523     Document Type: Article

References (45)

1. Torphy, T. J. 1998. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157: 351-370.
2. Barnette, M. S., and D. C. Underwood. 2000. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr. Opin. Pulm. Med. 6: 164-169.
3. Banner, K. H., and M. A. Trevethick. 2004. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol. Sci. 25: 430-436.
4. Conti, M., W. Richter, C. Menats, G. Livera, J. Y. Park, and C. Jin. 2003. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. 278: 5493-5496.
5. Houslay, M. D., and D. R. Adams. 2003. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370: 1-18.
6. Jin, S. L., F. J. Richard, W. P. Kuo, A. J. D'Ercole, and M. Conti. 1999. impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc. Natl. Acad Sci. USA 96: 11998-12003.
7. Jin, S. L., and M. Conti. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl. Acad. Sci. USA 99: 7628-7633.
8. Bundschuh, D. S., M. Eltze, J. Barsig, L. Wollin, A, Hatzelmann, and R. Beume. 2001. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 297: 280-290.
9. Barnette, M. S., S. B. Christensen, D. M. Essayan, M. Grous, U. Prabhakar, J. A. Rush, A. Kagey-Sobotka, and T. J. Torphy. 1998. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 284: 420-426.
10. Giembycz, M. A. 2002. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest Dis. 57: 48-64.
11. Manning, C. D., M. Burman, S. B. Christensen, L. B. Cieslinski, D. M. Essayan, M. Grous, T. J. Torphy, and M. S. Barnette. 1999. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol 128: 1393-1398.
12. Thompson, W. J., and M. M. Appleman. 1971. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10: 311-316.
13. Conti, M., B. G. Kasson, and A. J. Hsueh. 1984. Hormonal regulation of 3′,5′-adenosine monophosphate phosphodiesterases in cultured rat granulosa cells. Endocrinology 114: 2361-2368.
14. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
15. Harper, J. F., and G. Brooker. 1975. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′0 acetylation by acetic anhydride in aqueous solution. J. Cyclic Nucleotide Res. 1: 207-218.
16. Tenor, H., A. Hatzeltnann, R. Kupferschmidt, L. Stanciu, R. Djukanovic. C. Schudt, A. Wendel, M, K. Church, and J. K. Shute. 1995. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy 25: 625-633.
17. Alvarez, R., C. Sette, D. Yang, R. M. Eglen, R. Wilhelm, E. R. Shelton, and M. Conti. 1995. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase. PDE-4D3. Mol. Pharmacol. 48; 616-622.
18. Gantner, F., R. Kupferschmidt, C. Schudt, A. Wendel, and A. Hatzelmann. 1997. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-α release by PDE inhibitors, Br. J. Pharmacol. 121: 221-231.
19. Barber, R., G, S. Baillie, R. Bergmann, M. C. Shepherd, R. Sepper, M. D. Houslay, and G. V. Heeke. 2004. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am. J. Physiol. 287: L332-L343.
20. Bender, A. T., C. L. Ostenson, D. Giordano, and J. A. Beavo. 2004. Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression. Cell. Signal. 16: 365-374.
21. Kelly, J. J., P. J. Bames, and M. A. Giembycz. 1998. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors. Br. J. Pharmacol. 124: 129-140.
22. Shepherd, M. C., G. S. Baillie, D. I. Stirling, and M. D. Houslay. 2004. Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br. J. Pharmacol. 142: 339-351.
23. Turner, N. C., L. J. Wood, F. M. Burns, T. Gueremy, and J. E. Souness. 1993. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages. Br. J. Pharmacol. 108: 876-883.
24. Caamano, J., J. Alexander, L. Craig, R. Bravo, and C. A. Hunter. 1999. The NF-κB family member RelB is required for innate and adaptive immunity to Toxoplasma gondii. J. lmmunol 163: 4453-4461.
25. Bonizzi, G., and M. Karin. 2004. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
26. Claveau, D., S. L. Chen, S. O'Keefe, D. M. Zaller, A. Styhler, S. Liu, Z. Huang, D. W. Nicholson, and J. A. Mancini. 2004. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 (4-[2-(3,4-bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxy propan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J. Pharmacol Exp Ther. 310: 752-760.
27. Hatzelmann, A., and C. Schudt. 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297: 267-279.
28. Krakstad, C., A. E. Christensen, and S. O. Doskeland. 2004. CAMP protects neutrophils agains: TNF-α-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). J. Leukocyte Biol. 76: 641-647.
29. Beutler, B., and G. E. Grau. 1993. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit. Care Med. 21: S423-S435.
30. Taffet, S. M., K. J. Singhel, J. F. Overholtzer, and S. A. Shurtleff. 1989. Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol. 120: 291-300.
31. Procopio, D. O., M. M. Teixeira, M. M. Camargo, L. R. Travassos, M. A. Ferguson, I. C. Almeida, and R. T. Gazzinelli. 1999. Differential inhibitory mechanism of cyclic AMP on TNF-α and IL-12 synthesis by macrophages exposed to microbial stimuli. Br. J. Pharmacol, 127: 1195-1205.
32. Takahashi, N., T Tetsuka, H. Uranishi, and T. Okamoto. 2002. Inhibition of the NF-κB Iran scriptional activity by protein kinase A. Eur. J. Biochem. 269: 4559-4565.
33. Leceta, J., R. P. Gomariz, C. Martinez, C. Abad, D. Ganea, and M. Delgado. 2000. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann. NY Acad. Sci. 921: 92-102.
34. Delgado, M, and D. Ganea. 2001. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-κB-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J. Biol. Chem. 276: 369-380.
35. Zhong, H., H. Su Yang, H, Erdjument-Bromage, P. Tempst, and S. Ghosh. 1997. The transeriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 89; 413-424.
36. Dodge, K. L., S. Khouangsathiene, M. S. Kapiloff, R. Mouton, E. V. Hill, M. D. Houslay, L. K. Langeberg, and J. D. Scott. 2001. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase CAMP signaling module. EMBO J. 20: 1921-1930.
37. Tasken, K. A., P. Collas, W. A. Kemmner, O. Witczak, M. Conti, and K. Tasken. 2001. Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J. Biol. Chem. 276: 21999-22002.
38. Arp, J., M. G. Kirchhof, M. L. Baroja, S. H. Nazarian, T. A. Chau, C. A. Strathdee. E. H. Ball, and J. Madrenas. 2003. Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation. Mol. Cell. Biol 23: 8042-8057.
39. Juergens, U. R., V. Degenhardt, M. Stober, and H. Vetter. 1999. New insights in the bronchodilatory and anti-inflammatory mechanisms of action of theophylline. Arzneim.-Forsch. 49: 694-698.
40. Verghese, M. W., R. T. McConnell, J. M. Lenhard, L. Hamacher, and S. L. Jin. 1995. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol. 47: 1154-1171.
41. D'Sa, C., L. M. Tolbert, M. Conti, and R. S. Duman. 2002. Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J. Neurochem. 81: 745-757.
42. Giembycz, M. A. 2002. 4D or not 4D: the emetogenic basis of PDE4 inhibitors uncovered? Trends Pharmacol. Sci. 23: 548.
43. Lamontagne, S., E. Meadows, P. Luk, D. Normandin, E. Muise, L. Boulet, D. J. Pon, A. Robichaud, G. S. Robertson, K. M. Metters, and F. Nantel. 2001. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res. 920: 84-96.
44. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110: 1045-1052.
45. Conti, M, 2004. A view into the catalytic pocket of cyclic nucleotide phosphodiesterases. Nat. Struct. Mol. Biol. 11: 809-810.